These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4546215)

  • 1. Proceedings: Further studies on the mechanisms of blood pressure lowering effect of L-DOPA and a peripheral decarboxylase inhibitor in hypertensive rats.
    Nakamura K; Nakamura K
    Jpn Heart J; 1974 Mar; 15(2):187-8. PubMed ID: 4546215
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of L-dopa and inhibitors of decarboxylase and monoamine oxidase on brain noradrenaline levels and blood pressure in spontaneously hypertensive rats.
    Yamori Y; De Jong W; Yamabe H; Lovenberg W; Sjoerdsma A
    J Pharm Pharmacol; 1972 Sep; 24(9):690-5. PubMed ID: 4404071
    [No Abstract]   [Full Text] [Related]  

  • 3. [Potentiation of the central effect of DOPA after selective inhibition of extracerebral decarboxylase].
    Gaillard JM; Schaeppi R; Tissot R
    Arch Int Pharmacodyn Ther; 1969 Aug; 180(2):423-37. PubMed ID: 5348411
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of intravenously administered DOPA on the blood pressure in pretreated alpha-methyl-DOPA hypertensives. Studies on the blood pressure-lowering mechanism of alpha-methyl-DOPA].
    SCHAER H; ZIEGLER WH
    Klin Wochenschr; 1962 Sep; 40():959-62. PubMed ID: 13976633
    [No Abstract]   [Full Text] [Related]  

  • 5. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 7. Anorexigenic effects of d-amphetamine and l-DOPA in the rat.
    Sanghvi IS; Singer G; Friedman E; Gershon S
    Pharmacol Biochem Behav; 1975; 3(1):81-6. PubMed ID: 1129359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine: mediator of brain polysome disaggregation after L-dopa.
    Weiss BF; Munro HN; Ordonez LA; Wurtman RJ
    Science; 1972 Aug; 177(4049):613-6. PubMed ID: 4403139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of the cardiovascular effects of L-dopa in anesthetized dogs by inhibitors of enzymes involved in catecholamine metabolism.
    Robson RD
    Circ Res; 1971 Jun; 28(6):662-70. PubMed ID: 4325846
    [No Abstract]   [Full Text] [Related]  

  • 10. Exploration of the anti-depressant potential of L-dopa.
    Sanghvi I; Urquiaga X; Gershon S
    Psychopharmacologia; 1971; 20(2):118-27. PubMed ID: 5104531
    [No Abstract]   [Full Text] [Related]  

  • 11. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1970 Aug; 22(8):553-60. PubMed ID: 4394527
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of brain 5-hydroxytryptamine in the central action of L-DOPA.
    Maj J; Pawlowski L; Sarnek J
    Adv Biochem Psychopharmacol; 1974; 10():253-6. PubMed ID: 4846541
    [No Abstract]   [Full Text] [Related]  

  • 13. The actions of dihydroxyphenylalanine and dihydroxyphenylserine on the sleep-wakefulness cycle of the rat after peripheral decarboxylase inhibition.
    Altier H; Moldes M; Monti JM
    Br J Pharmacol; 1975 May; 54(1):101-6. PubMed ID: 166716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study, in the dog, of effect of alpha and beta blocking agents on arterial pressure effects of L-Dopa].
    Patay M; Lacroix P; Le Clec'h G; Linée P; Van den Driessche J
    C R Seances Soc Biol Fil; 1973; 167(8):1266-74. PubMed ID: 4152729
    [No Abstract]   [Full Text] [Related]  

  • 15. On the mechanism of L-dopa-induced postural hypotension in the cat.
    Dhasmana KM; Spilker BA
    Br J Pharmacol; 1973 Mar; 47(3):437-51. PubMed ID: 4147189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
    Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H
    Arzneimittelforschung; 1970 Jul; 20(7):934-5. PubMed ID: 4918921
    [No Abstract]   [Full Text] [Related]  

  • 17. [Role of central catecholamines in blood pressure regulation of spontaneously hypertensive rat].
    Yamori Y
    Saishin Igaku; 1971 Nov; 26(11):2063-73. PubMed ID: 4946774
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of large doses of L-DOPA on the cerebral electrical activity of rabbits (interaction with the metabolism of 5-HT)].
    Gaillard JM; Friedli P; Tissot R
    Arch Int Pharmacodyn Ther; 1973 Apr; 202(2):342-52. PubMed ID: 4694370
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of clonidine on the 5-hydroxytryptamine and 5-hydroxyindoleacetic acid brain levels.
    Maj J; Baran L; Grabowska M; Sowińska H
    Biochem Pharmacol; 1973 Nov; 22(21):2679-83. PubMed ID: 4763602
    [No Abstract]   [Full Text] [Related]  

  • 20. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.